Vertex, Inc. (NASDAQ: VERX) (“Vertex” or the “Company”), a leading global provider of indirect tax solutions, today announced financial results for its third quarter ended September 30, 2025 and the ...

Vertex ( ($VERX) ) has shared an update. On October 30, 2025, Vertex‘s Board of Directors authorized a stock repurchase program for up to $150 ...

Vertex, Inc. shares have plunged over 60% YTD, but valuation is now compelling after a post-earnings dip. Learn more about VERX stock here.

The stock, which is down more than 61% in 2025, sold off after reporting a Q3 EPS beat missing on revenue expectations.

Vertex stock dipped late Monday on a mixed third-quarter report, with the lion's share of its sales beat coming from its ...

If you're an individual retail investor searching for healthcare stocks you can buy and hold for at least 20 years, here are ...

On Wednesday, November 12, Scholarship America, the nation's largest scholarship administrator, will host the second annual Irving Innovation Awards in Washington, D.C. at The Dupont Circle Hotel.

AAVantgarde also received continued strong support from existing investors Longwood Fund and Sofinnova Partners. The proceeds from the financing will support: Completion of clinical PoC of AAVantgarde ...

Get insights from Vertex Pharmaceuticals' Q3 2025 earnings call—revenue growth, pipeline milestones, and outlook for ALYFTREK, CASGEVY, and JOURNAVX.

BOSTON (AP) — BOSTON (AP) — Vertex Pharmaceuticals Inc. (VRTX) on Monday reported third-quarter net income of $1.08 billion. On a per-share basis, the Boston-based company said it had profit of $4.20.

Share Market Highlights - Find here all the highlights related to Sensex, Nifty, BSE, NSE, share prices and Indian stock ...